New data suggest that vildagliptin is a safe and efficient therapy for new-onset diabetes after transplantation (NODAT). In this phase II, randomized, placebo-controlled trial, which included 33 kidney transplant recipients, vildagliptin therapy resulted in substantial improvements in levels of 2-h plasma glucose (derived using an oral glucose tolerance test) and HbA1c from baseline, at 3 months of follow-up.